PGE2 inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function
Ludwig Cancer Research · Swiss Cancer Center Léman · +6 more institutions
Abstract
Abstract Expansion of antigen-experienced CD8 + T cells is critical for the success of tumour-infiltrating lymphocyte (TIL)-adoptive cell therapy (ACT) in patients with cancer 1 . Interleukin-2 (IL-2) acts as a key regulator of CD8 + cytotoxic T lymphocyte functions by promoting expansion and cytotoxic capability 2,3 . Therefore, it is essential to comprehend mechanistic barriers to IL-2 sensing in the tumour microenvironment to implement strategies to reinvigorate IL-2 responsiveness and T cell antitumour responses. Here we report that prostaglandin E2 (PGE 2 ), a known negative regulator of immune response in the tumour microenvironment 4,5 , is present at high concentrations in tumour tissue from patients…
Citation impact
- FWCI
- 39.86
- Percentile
- 100%
- References
- 60
Authors
41- MMMatteo MorottiCorresponding
Ludwig Cancer Research, Swiss Cancer Center Léman, University of Lausanne
- AJAlizée J Grimm
Ludwig Cancer Research, Swiss Cancer Center Léman, University of Lausanne
- HCHelen Carrasco Hope
Ludwig Cancer Research, University of Lausanne
- MAMarion Arnaud
Ludwig Cancer Research, Swiss Cancer Center Léman, University of Lausanne
- MDMathieu Desbuisson
Ludwig Cancer Research, Swiss Cancer Center Léman, University of Lausanne
Topics & keywords
- Cell biology
- Function (biology)
- Signalling
- Chemistry
- Biology
- Good health and well-being